Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues.
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005340:Fibrinogen / Q000494:pharmacology; D007457:Iodine Radioisotopes; D010974:Platelet Aggregation / Q000187:drug effects*; D010980:Platelet Membrane Glycoproteins; D011449:Prostaglandin Endoperoxides / Q000494:pharmacology*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology*; D011463:Prostaglandins H / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000187:drug effects*
D007457:Iodine Radioisotopes; D010980:Platelet Membrane Glycoproteins; D011449:Prostaglandin Endoperoxides; D011450:Prostaglandin Endoperoxides, Synthetic; D011463:Prostaglandins H; D011956:Receptors, Cell Surface; D000244:Adenosine Diphosphate; C013824:azo analog II; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C010959:5'-(4-fluorosulfonylbenzoyl)adenosine; D000255:Adenosine Triphosphate; D005340:Fibrinogen; D000241:Adenosine